Stockscreener 앱 받기
9.06
9.41%
-0.98
시간 외 거래:
9.09
0.03
+0.33%
전일 마감가:
$10.04
열려 있는:
$9.97
하루 거래량:
1.06M
Relative Volume:
0.96
시가총액:
$483.36M
수익:
$1.02B
순이익/손실:
$-757.20M
주가수익비율:
-0.6138
EPS:
-14.76
순현금흐름:
$-257.90M
1주 성능:
-0.60%
1개월 성능:
+14.12%
6개월 성능:
+113.50%
1년 성능:
+7.63%
1일 변동 폭
$9.06
$10.02
1주일 범위
$8.85
$10.10
52주 변동 폭
$4.02
$12.73
Emergent Biosolutions Inc Stock (EBS) Company Profile
명칭
Emergent Biosolutions Inc
전화
240-631-3200
주소
300 PROFESSIONAL DR, GAITHERSBURG, MD
EBS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EBS
Emergent Biosolutions Inc
|
9.06 | 535.65M | 1.02B | -757.20M | -257.90M | -14.76 |
|
ZTS
Zoetis Inc
|
141.09 | 63.55B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.72 | 44.47B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.00 | 40.17B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.03 | 22.99B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
439.99 | 20.14B | 3.08B | 1.24B | 1.07B | 25.61 |
Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-30 | 개시 | H.C. Wainwright | Buy |
| 2024-08-22 | 개시 | Rodman & Renshaw | Buy |
| 2024-03-07 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2023-11-20 | 재개 | JP Morgan | Underweight |
| 2023-08-29 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2023-04-10 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2023-03-17 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-11-10 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2022-04-29 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2022-01-20 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2021-11-08 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2021-05-05 | 다운그레이드 | Argus | Buy → Hold |
| 2021-04-07 | 개시 | The Benchmark Company | Buy |
| 2021-02-24 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2021-02-19 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2021-01-08 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-09-14 | 재개 | JP Morgan | Neutral |
| 2020-07-31 | 재확인 | Chardan Capital Markets | Buy |
| 2019-09-12 | 개시 | Guggenheim | Buy |
| 2019-09-04 | 업그레이드 | Wells Fargo | Market Perform → Outperform |
| 2018-11-02 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-08-03 | 재확인 | Chardan Capital Markets | Buy |
| 2018-06-13 | 개시 | Argus | Buy |
| 2018-04-25 | 다운그레이드 | Wells Fargo | Outperform → Market Perform |
| 2018-01-24 | 개시 | Goldman | Neutral |
| 2018-01-16 | 재확인 | Chardan Capital Markets | Buy |
| 2016-06-28 | 재확인 | Singular Research | Buy |
| 2016-04-15 | 개시 | Chardan Capital Markets | Buy |
| 2016-03-28 | 개시 | Singular Research | Buy |
| 2016-02-19 | 개시 | Wells Fargo | Outperform |
| 2014-05-15 | 개시 | Summer Street Research | Buy |
| 2011-05-31 | 재확인 | WBB Securities | Strong Buy |
| 2011-01-10 | 재확인 | Wedbush | Outperform |
| 2010-11-05 | 재확인 | Wedbush | Outperform |
| 2010-08-18 | 업그레이드 | WBB Securities | Buy → Strong Buy |
| 2010-08-06 | 재확인 | Caris & Company | Buy |
모두보기
Emergent Biosolutions Inc 주식(EBS)의 최신 뉴스
Short interest data insights for Emergent BioSolutions Inc.July 2025 Spike Watch & Expert Approved Momentum Trade Ideas - newser.com
How strong is Emergent BioSolutions Inc. stock balance sheetJuly 2025 Update & Consistent Profit Alerts - newser.com
Emergent Biosolutions (NYSE:EBS) Given "Sell (D)" Rating at Weiss Ratings - MarketBeat
Is Emergent BioSolutions Inc. (ER4) stock dividend growth reliableQuarterly Trade Summary & Real-Time Sentiment Analysis - newser.com
Emergent BioSolutions Inc.'s (NYSE:EBS) Shares Bounce 31% But Its Business Still Trails The Industry - simplywall.st
Emergent BioSolutions to Report Third Quarter 2025 Financial Results on October 29, 2025 - The Manila Times
Emergent BioSolutions Inc. Announces Conference Call for Third Quarter 2025 Financial Results - Quiver Quantitative
Emergent Biosolutions (NYSE:EBS) Stock Price Up 5.3%Still a Buy? - MarketBeat
Emergent Biosolutions (NYSE:EBS) Share Price Crosses Above 200 Day Moving AverageShould You Sell? - MarketBeat
Quantitative breakdown of Emergent BioSolutions Inc. recent moveTrade Ideas & Growth Focused Entry Reports - newser.com
Why Emergent BioSolutions Inc. (ER4) stock is listed among top recommendationsWeekly Market Summary & Free Safe Entry Trade Signal Reports - newser.com
Is Emergent BioSolutions Inc. (ER4) stock a buy during volatile marketsJuly 2025 Opening Moves & Short-Term High Return Ideas - newser.com
Published on: 2025-10-05 04:23:16 - newser.com
Is Emergent BioSolutions Inc. stock a top pick in earnings season2025 Market Sentiment & Fast Moving Trade Plans - newser.com
Relative strength of Emergent BioSolutions Inc. in sector analysisWeekly Trend Summary & Long-Term Capital Growth Ideas - newser.com
How to interpret RSI for Emergent BioSolutions Inc. stockPortfolio Update Report & Weekly Setup with ROI Potential - newser.com
Strategies to average down on Emergent BioSolutions Inc.Portfolio Value Report & AI Powered Market Trend Analysis - newser.com
Multi factor analysis applied to Emergent BioSolutions Inc.CEO Change & Entry Point Strategy Guides - newser.com
Is Emergent BioSolutions Inc. stock poised for growth2025 Stock Rankings & Consistent Profit Alerts - newser.com
Emergent BioSolutions Inc Stock Analysis and ForecastVolatility Index Analysis & Big Profit Small Budget - earlytimes.in
Is Emergent BioSolutions Inc ER4 a good long term investmentMarket Insider Reports & Affordable Investment Strategies - Early Times
Emergent Biosolutions Inc. $EBS Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Emergent BioSolutions Inc.'s (NYSE:EBS) large institutional owners must be happy as stock continues to impress, up 10% over the past week - Yahoo Finance
Emergent BioSolutions Inc. Reaffirms Commitment to Combat Opioid Crisis Through Awareness and Access to Naloxone Products - Quiver Quantitative
45% of Retail Workers Have Witnessed Naloxone Use: Emergent BioSolutions Tackles Workplace Opioid Crisis - Stock Titan
Emergent BioSolutions stock maintains Buy rating at H.C. Wainwright on $29M deal - Investing.com Canada
Emergent Biosolutions Inc (EBS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.54%
1.16%
자본화:
|
볼륨(24시간):